Related references
Note: Only part of the references are listed.Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy
Lucia Masarova et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression
Stephan Bartels et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era
Jong-Mi Lee et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
Damien Luque Paz et al.
BLOOD ADVANCES (2021)
Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression
Julia T. Geyer et al.
HAEMATOLOGICA (2020)
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression
Laurane Cottin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature
Giacomo Coltro et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2020)
Leukemia secondary to myeloproliferative neoplasms
Andrew J. Dunbar et al.
BLOOD (2020)
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era
Lucia Masarova et al.
CANCER (2020)
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia
Christopher B. Benton et al.
CANCER (2019)
Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
Rangit R. Vallapureddy et al.
BLOOD CANCER JOURNAL (2019)
Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?
Alain Antoine Mina et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias) 2017 Society for Hematopathology/European Association for Haematopathology Workshop Report
Robert P. Hasserjian et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach
Alessandra Iurlo et al.
HEMATOLOGICAL ONCOLOGY (2019)
Late polycythemic transformation in JAK2-mutated essential thrombocythemia patients-Characteristics along with a validation of 2016 WHO criteria
Patryk Sobieralski et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Myelofibrosis in 2019: moving beyond JAK2 inhibition
Michael Schieber et al.
BLOOD CANCER JOURNAL (2019)
Persistent Basophilia May Suggest an Accelerated Phase in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia
Jerome Dobrowolski et al.
FRONTIERS IN ONCOLOGY (2019)
Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis
Zhihong Hu et al.
HUMAN PATHOLOGY (2019)
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
J-C Hernandez-Boluda et al.
LEUKEMIA (2018)
Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia
Jennifer Chapman et al.
MODERN PATHOLOGY (2018)
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group
Jason Aynardi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Barbara Mora et al.
HAEMATOLOGICA (2018)
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
Anna Sophia McKenney et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
Barbara Mora et al.
LEUKEMIA RESEARCH (2018)
Outcomes and predictors of survival in blast phase myeloproliferative neoplasms
Guido Lancman et al.
LEUKEMIA RESEARCH (2018)
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Francesca Palandri et al.
SEMINARS IN HEMATOLOGY (2018)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Barbara Mora et al.
HAEMATOLOGICA (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Polycythemia vera and essential thrombocythemia: algorithmic approach
Alessandro M. Vannucchi et al.
CURRENT OPINION IN HEMATOLOGY (2018)
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
Terra L. Lasho et al.
BLOOD ADVANCES (2018)
Bone marrow findings in blast phase of polycythemia vera
Juliana E. Hidalgo Lopez et al.
ANNALS OF HEMATOLOGY (2018)
Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients
F. Passamonti et al.
LEUKEMIA (2017)
Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients
Umberto Gianelli et al.
HISTOPATHOLOGY (2017)
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
A. Tefferi et al.
LEUKEMIA (2017)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
F. Passamonti et al.
LEUKEMIA (2017)
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
Lucia Masarova et al.
LEUKEMIA RESEARCH (2017)
Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2017)
Myeloproliferative neoplasms: from origins to outcomes
Jyoti Nangalia et al.
BLOOD (2017)
Monocytosis in polycythemia vera: Clinical and molecular correlates
Daniela Barraco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli et al.
BLOOD (2017)
Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study
Hans Michael Kvasnicka et al.
HISTOPATHOLOGY (2016)
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
D. Pietra et al.
LEUKEMIA (2016)
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
Giada Rotunno et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
Paola Guglielmelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis
Lucia Masarova et al.
BLOOD (2016)
Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms
Magdalena Czader et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Olga Pozdnyakova et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities
Christopher B. Benton et al.
LEUKEMIA RESEARCH (2015)
Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications
Leonardo Boiocchi et al.
MODERN PATHOLOGY (2015)
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
P. Guglielmelli et al.
BLOOD CANCER JOURNAL (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera
Mario Tiribelli et al.
ANNALS OF HEMATOLOGY (2015)
The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis
T. Barbui et al.
LEUKEMIA (2015)
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution
X. Cabagnols et al.
LEUKEMIA (2015)
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi et al.
BLOOD (2014)
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
Ayalew Tefferi et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
Juan-Carlos Hernandez-Boluda et al.
HAEMATOLOGICA (2014)
Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
Umberto Gianelli et al.
MODERN PATHOLOGY (2014)
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
A. Tefferi et al.
LEUKEMIA (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
P. Guglielmelli et al.
LEUKEMIA (2014)
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Raajit Rampal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
Elisa Rumi et al.
BLOOD (2013)
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Alfonso Quintas-Cardama et al.
CLINICAL CANCER RESEARCH (2013)
Two novel NPM1 mutations in an acute myeloid leukemia patient transformed from primary myelofibrosis
S. H. Park et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2013)
Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease
Leonardo Boiocchi et al.
MODERN PATHOLOGY (2013)
Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage
Leonardo Boiocchi et al.
MODERN PATHOLOGY (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
Umberto Gianelli et al.
MODERN PATHOLOGY (2012)
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm
Elisa Rumi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
Paola Guglielmelli et al.
BLOOD (2009)
Leukocytosis at Diagnosis and the Risk of Subsequent Thrombosis in Patients With Low-Risk Essential Thrombocythemia and Polycythemia Vera
Naseema Gangat et al.
CANCER (2009)
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Francesco Passamonti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis:: de-novo origin?
L. Pasqualucci et al.
LEUKEMIA (2008)
Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis
Claudia Vener et al.
BLOOD (2008)
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
Giovanni Barosi et al.
BLOOD (2007)
Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis
M. A. Elliott et al.
LEUKEMIA RESEARCH (2007)
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Prognostic significance of monocytosis in patients with myeloproliferative disorders
M Beran et al.
LEUKEMIA & LYMPHOMA (2006)
Granulocytic sarcoma of megakaryoblastic differentiation in the lymph nodes terminating as acute megakaryoblastic leukemia in a case of chronic idiopathic myelofibrosis persisting for 16 years
Y Hirose et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Share Paper
